

## Original Article

**Cite this article:** Steen NE *et al* (2020). Metabolic dysfunctions in the kynurenine pathway, noradrenergic and purine metabolism in schizophrenia and bipolar disorders. *Psychological Medicine* **50**, 595–606. <https://doi.org/10.1017/S0033291719000400>

Received: 19 June 2018  
Revised: 12 November 2018  
Accepted: 14 February 2019  
First published online: 14 March 2019

### Key words:

Metabolomics; psychotic disorders; tryptophan; tyrosine

### Author for correspondence:

Nils Eiel Steen, E-mail: [n.e.steen@medisin.uio.no](mailto:n.e.steen@medisin.uio.no)

# Metabolic dysfunctions in the kynurenine pathway, noradrenergic and purine metabolism in schizophrenia and bipolar disorders

Nils Eiel Steen<sup>1</sup>, Ingrid Dieset<sup>1</sup>, Sigrun Hope<sup>1,2</sup>, Trude S.J. Vedal<sup>1</sup>,  
Olav B. Smeland<sup>1,3</sup>, Wayne Matson<sup>4</sup>, Rima Kaddurah-Daouk<sup>5,6,7</sup>, Ingrid Agartz<sup>1,8</sup>,  
Ingrid Melle<sup>1</sup>, Srdjan Djurovic<sup>1,9,10</sup>, Erik G. Jönsson<sup>1,11</sup>, Mikhail Bogdanov<sup>12</sup>  
and Ole A. Andreassen<sup>1</sup>

<sup>1</sup>NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway; <sup>2</sup>Department of Neurohabilitation, Oslo University Hospital, Oslo, Norway; <sup>3</sup>Department of Neuroscience, University of California San Diego, La Jolla, CA 92093, USA; <sup>4</sup>Bedford VA Medical Center, Bedford, MA, USA; <sup>5</sup>Duke Molecular Physiology Institute, Duke University, Durham, NC, USA; <sup>6</sup>Duke Institute of Brain Sciences, Duke University, Durham, NC, USA; <sup>7</sup>Department of Medicine, Duke University, Durham, NC, USA; <sup>8</sup>Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway; <sup>9</sup>Department of Medical Genetics, Oslo University Hospital, Oslo, Norway; <sup>10</sup>Department of Clinical Science, University of Bergen, Bergen, Norway; <sup>11</sup>Department of Clinical Neuroscience, Centre for Psychiatric Research, Karolinska Institutet, Stockholm, Sweden and <sup>12</sup>Weill Medical College, Cornell University, New York, USA

## Abstract

**Background.** We aimed at exploring potential pathophysiological processes across psychotic disorders, applying metabolomics in a large and well-characterized sample of patients and healthy controls.

**Methods.** Patients with schizophrenia and bipolar disorders ( $N = 212$ ) and healthy controls ( $N = 68$ ) had blood sampling with subsequent metabolomics analyses using electrochemical coulometric array detection. Concentrations of 52 metabolites including tyrosine, tryptophan and purine pathways were compared between patients and controls while controlling for demographic and clinical characteristics. Significant findings were further tested in medication-free subsamples.

**Results.** Significantly decreased plasma concentrations in patients compared to healthy controls were found for 3-hydroxykynurenine (3OHKY,  $p = 0.0008$ ), xanthurenic acid (XANU,  $p = 1.5 \times 10^{-5}$ ), vanillylmandelic acid (VMA,  $p = 4.5 \times 10^{-5}$ ) and metanephrine (MN,  $p = 0.0001$ ). Plasma concentration of xanthine (XAN) was increased in the patient group ( $p = 3.5 \times 10^{-5}$ ). Differences of 3OHKY, XANU, VMA and XAN were replicated across schizophrenia spectrum disorders and bipolar disorders subsamples of medication-free individuals.

**Conclusions.** Although prone to residual confounding, the present results suggest the kynurenine pathway of tryptophan metabolism, noradrenergic and purinergic system dysfunction as trait factors in schizophrenia spectrum and bipolar disorders. Of special interest is XANU, a metabolite previously not found to be associated with bipolar disorders.

## Introduction

Schizophrenia and bipolar disorder are highly heritable disorders with phenotypic and genotypic overlap (Lichtenstein *et al.*, 2009; Tesli *et al.*, 2014). Despite intensive research, the underlying mechanisms are still unresolved (Grande *et al.*, 2016; Owen *et al.*, 2016). To enable better treatments and potentially preventive measures, there is a continuing need for research pursuing pathophysiological components by taking advantage of new and advanced methods for mapping of biological processes.

The complexity of neuroactive substances and signaling involved in mental processes imply the need for comprehensive assessments of signaling pathways and physiological processes to unveil the mechanisms of severe mental disorders. Metabolomics, the analysis of a broad spectrum of metabolites from the metabolic processes and interactions in the body, is an emerging method enabling characterization of the actual metabolic status of an individual (Kaddurah-Daouk and Krishnan, 2009; Guest *et al.*, 2015; Sethi and Brietzke, 2015). Metabolomics have already been applied in both central and peripheral tissues in severe mental disorders and other brain disorders (Yao *et al.*, 2010a, 2010b, 2012; Condray *et al.*, 2011; Kaddurah-Daouk *et al.*, 2012, 2013; Motsinger-Reif *et al.*, 2013; Fazio *et al.*, 2015; Gupta *et al.*, 2016; Rotroff *et al.*, 2016; Zhang *et al.*, 2016). These studies have identified several potential

biomarkers (Oresic *et al.*, 2011; Kaddurah-Daouk *et al.*, 2012; Yoshimi *et al.*, 2016), being able to distinguish diagnostic groups from healthy controls (Bicikova *et al.*, 2013; Motsinger-Reif *et al.*, 2013; Fukushima *et al.*, 2014; Liu *et al.*, 2014; Xu *et al.*, 2014; Tasic *et al.*, 2017). Disease-related processes indicated by biomarkers from metabolomics studies include such as neurotransmission, energy metabolism, mitochondrial functioning and oxidative stress (Sethi and Brietzke, 2015).

Despite promising results, metabolomics is a novel approach and studies of severe mental disorders suffer from essential shortcomings. These include potential for confounding effects of medication and other extraneous factors (Turck and Filiou, 2015) and risk of type 1 errors due to multiple testing based on a broad range of metabolites. To overcome these limitations, large and well-characterized samples of patients and healthy controls are needed to be able to control for several confounders, including analyzes of metabolite levels in individuals free from psychotropic drugs and other medications. Moreover, the use of large samples across psychotic disorders makes it possible to alleviate the issue of multiple testing. As bipolar disorders and schizophrenia spectrum disorders are pathophysiological related disorders (Cardno and Owen, 2014; Volk *et al.*, 2016) metabolite findings of one group could be tested in the other diagnostic group. Being able to replicate findings across the two disorders would strengthen the findings and simultaneously indicate mechanisms in common for the disorders.

In the present metabolomics study, we investigated a predefined range of metabolites including monoamine-, purine- and sulfur amino acid pathways, in a large sample of both bipolar and schizophrenia spectrum disorders. We aimed at identifying pathophysiologically related metabolites targeting well-known candidate pathways of psychosis spectrum disorders mechanisms. We hypothesized dysregulations mainly related to tryptophan, tyrosine and purine pathways (Fig. 1) as established pathophysiological candidates involving dopamine, norepinephrine, epinephrine, serotonin and purine metabolism (Gysin *et al.*, 2007; Michel *et al.*, 2011; Ortiz *et al.*, 2015; Grande *et al.*, 2016; Owen *et al.*, 2016; Lieberman and First, 2018), and with conclusions based on replicated findings in the two diagnostic groups in medication-free individuals.

## Methods

### Participants

Patients were included through the ongoing Thematically Organized Psychosis (TOP) Study carried out at the University Hospitals of Oslo, Norway. General inclusion criteria for the TOP study are (1) being registered in the psychiatric services of any one of the participating hospitals, (2) age 18–65 years, (3) meeting the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria for bipolar or schizophrenia spectrum disorders, and (4) to be willing and able to give written, informed consent to participation. General exclusion criteria are a history of moderate or severe head injury, serious somatic illness, neurological disorder and mental retardation.

Included in the current substudy were consecutively referred patients ( $N = 212$ ) and a healthy control group ( $N = 68$ ) included from 2004 to 2013, with metabolomics measurements. Duration of illness [median (interquartile range)] was 4 (9) years for the total patient sample and 7 (16) years for the unmedicated ( $N = 52$ ) patients. The patients had a DSM-IV Schizophrenia

and Other Psychotic Disorders diagnosis, excluding Psychotic Disorder Due to a General Medical Condition and Substance-Induced Psychotic Disorder, in the following termed 'schizophrenia spectrum' [SCZ,  $N = 139$  (25 unmedicated)], or any type of DSM-IV Bipolar Disorder diagnosis, in the following termed 'bipolar disorder' [BD,  $N = 73$  (27 unmedicated)]. The reason for not receiving medication was usually early phase of disease or discontinuation. The healthy control group [ $N = 68$ , (50 unmedicated), 18 typically used over-the-counter painkillers, contraceptives or antiallergics] was randomly selected from statistical records from the same catchment area as the patients. Table 1 shows the sample characteristics.

### Clinical assessments

Inclusion and diagnostic interviews were done by trained medical doctors and psychologists using The Structured Clinical Interview for DSM-IV Axis I Disorders, SCID 1 (First *et al.*, 1995). The Inventory of Depressive Symptomatology-Clinician Rated (IDS-C, BD group) (Rush *et al.*, 1996), Calgary depression scale for schizophrenia (CDSS, SCZ group) (Addington *et al.*, 1990), Young Mania Rating Scale (YMRS) (Young *et al.*, 1978), the Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) (Kay *et al.*, 1987), and Global Assessment of Functioning, symptom scale (GAF-S) (Pedersen *et al.*, 2007) were used for symptom assessments (Table 1).

In addition, a series of clinical characteristics were assessed including illicit drug use (number of times used in the last 2 weeks), use of tobacco (yes/no), body mass index (BMI) and diet (complete list given in Table 1). Diet was assessed by interview as very or moderate unhealthy or healthy during the last 6 months, and dichotomized as unhealthy (very or moderate) or healthy in the analyses. The items early morning awakening from IDS and CDSS were used as a measure of sleep pattern (Mukherjee *et al.*, 2018).

### Sample collection and metabolomics concentration analyses

Blood was drawn from the antecubital vein in the morning while participants were fasting. The sample was centrifuged for 15 min at  $1200 \times g$  while the temperature was kept at  $4^\circ\text{C}$  in a cooled centrifuge. Then the plasma was rapidly collected in a conic tube and immediately frozen at  $-80^\circ\text{C}$ . All samples were collected and prepared by the same personnel at the same laboratory.

Plasma samples were analyzed using a liquid chromatography electrochemical array (LCECA) platform that has been extensively validated and used in our prior studies in neurodegenerative and psychiatric disorders (Rozen *et al.*, 2005; Bogdanov *et al.*, 2008; Johansen *et al.*, 2009; Kaddurah-Daouk *et al.*, 2013; Zhu *et al.*, 2013). Targeted assays with the LCECA platform include compounds from the tyrosine, tryptophan, purine and sulfur amino acid pathways, vitamins, oxidative, nitrative and methylation markers and a number of drugs and metabolites. The complete list of metabolites analyzed is shown in Table 2.

### Ethics

The investigation was carried out in accordance with the Declaration of Helsinki. After complete description of the study to the subjects, written informed consent was obtained. The Regional Ethics Committee and The Norwegian Data




Fig. 1. Metabolites of the (a) tryptophan, (b) purine and (c) tyrosine pathways assessed in the study.

**Table 1.** Demographic and clinical variables across the sample

	BD (N = 73)	SCZ (N = 139)	HC (N = 68)
Number (valid percent)			
Sex, males	33 (45.2)*	86 (61.9)	33 (48.5)
Use of illicit drug last 2 weeks	7 (9.7)	11 (8.5)	–
Use of alcohol last 2 weeks	51 (71.8)***	58 (46.0)	–
Use of tobacco	34 (46.6)	68 (50.4)	–
Healthy diet	58 (84.1)**	80 (61.1)	–
Median (interquartile range)			
Age	31.0 (19.0)	28.0 (14.0)	31.0 (16.0)
GAF-S	60.0 (12.0)***	40.0 (16.0)	–
SCI-PANSS, total score	43.5 (10.0)***	58.0 (21.0)	–
IDS, total score	14.0 (18.0)	–	–
CDSS, total score	–	4.0 (7.0) <sup>a</sup>	–
YMRS, total score	2.0 (5.0)	3.0 (10.0) <sup>a</sup>	–
Number of affective episodes	6.0 (19.5)***	1.0 (2.0)	–
Number of psychotic episodes	0.5 (1.0)***	1.0 (1.0)	–
BMI	24.1 (5.1)	24.9 (5.0)	24.5 (4.5) <sup>a</sup>

BD, Bipolar disorders; BMI, Body mass index; CDSS, Calgary depression scale for schizophrenia; GAF-S, Global assessment of functioning, symptom scale; HC, Healthy controls; IDS, Inventory of depressive symptomatology; SCI-PANSS, Structured clinical interview for the positive and negative syndrome scale; SCZ, Schizophrenia and other psychotic disorders (DSM IV, excluding Psychotic Disorder due to a General Medical Condition and Substance-Induced Psychotic Disorder); YMRS, Young mania rating scale.

<sup>a</sup>15.1% missing values for CDSS total score and 31.7% missing values for YMRS total score in the SCZ group; 17.6% missing values for BMI in the HC group. Other variables: 0–9.6% missing values per variable within each patient group.

\* $p < 0.05$ , \*\* $p < 0.01$  and \*\*\* $p < 0.001$  v. SCZ. HC did not differ significantly from the diagnostic groups on sex or age.

Inspectorate approved the study. The Norwegian Directorate of Health approved the biobank.

### Statistical analysis

For testing between-group differences of demographic and clinical data we used Mann–Whitney  $U$  test and  $\chi^2$  test for continuous and categorical variables, respectively (Table 1). Metabolite plasma concentrations were compared between all patients and healthy controls and between SCZ and BD with ANCOVA, applying adjustments with backward elimination of number of affective episodes, number of psychotic episodes (proxies for duration of illness and illness course), BMI, GAF-S (for comparison of SCZ and BD), age and sex. Due to skewed distributions, metabolite concentrations were transformed using logarithmic, square root and inverse transformations as appropriate. Number of psychotic and affective episodes were set at zero for healthy controls. The Mann–Whitney  $U$  test was used for variables not fulfilling criteria for parametric analyses (see Table 2).

To further test the significant associations of the main analyses for potential confounding of the demographic and clinical variables not recorded in healthy controls [use of illicit drugs, alcohol and tobacco; diet; level of symptoms (general; affective, including sleep pattern; and psychosis)], we first identified the variables significantly associated with metabolite concentrations in the patient group (Table 3). Secondly, we grouped patients according to being below or above (defined as equal or above) the median (continuous variables) and according to the categories (dichotomous variables) of these variables. We then compared metabolite concentrations of each of these subgroups of patients with those of the healthy control group. Spearman's rho was applied for

the association analyses between metabolite concentrations and continuous clinical variables and independent samples  $t$  tests were applied for analyses across groups (Mann–Whitney  $U$  test for 2,5 dihydroxyphenylacetic acid (HGA)) (Table 3).

Level of significance was set at  $p < 0.00096$  for the testing of metabolite concentration differences in the total patient sample of both medicated and medication-free individuals v. healthy controls, to correct for multiple statistical testing (a total of 52 metabolites). Significant findings in the total patient sample were further tested using ANCOVA with adjustments for sex and age in only medication-free individuals for replicated differences in both SCZ and BD separately at the level of  $p < 0.05$ ; significant findings in the psychosis spectrum group, SCZ, are only reported if findings in the more uniform group of patients with a schizophrenia specific diagnosis ( $SZ_{\text{diagn}}$ ) were insignificant.

## Results

### Metabolite concentrations in patients and healthy controls

#### Total patient sample v. healthy controls

Plasma concentrations of 3-hydroxykynurenine (3OHKY), xanthurenic acid (XANU), xanthine (XAN), vanillylmandelic acid (VMA) and metanephrine (MN) differed significantly in the total patient sample compared to the healthy controls in analyses independent of medication status. Lower concentrations in patients v. healthy controls were found for 3OHKY ( $F = 11.5$ ,  $df = 1$ ,  $p = 0.0008$ , Fig. 2a), XANU ( $F = 19.5$ ,  $df = 1$ ,  $p = 1.5 \times 10^{-5}$ , Fig. 2b), VMA ( $F = 17.2$ ,  $df = 1$ ,  $p = 4.5 \times 10^{-5}$ , Fig. 2c) and MN ( $F = 15.0$ ,  $df = 1$ ,  $p = 0.0001$ ). Higher plasma concentrations in patients v. healthy controls were found for XAN



**Table 2.** List of metabolites assessed

Tryptophan	Tyrosine
<i>Metabolites</i>	<i>Metabolites</i>
N-Acetyl-5-hydroxytryptamine <sup>a</sup>	3,4-Dihydroxymandelic acid
Anthranilic acid <sup>a</sup>	Dihydroxyphenylacetic acid
3-Hydroxyanthranilic Acid <sup>a</sup>	2,5 dihydroxyphenylacetic acid <sup>a</sup>
5-Hydroxyindoleacetic acid <sup>a</sup>	L-Dopa
3-Hydroxykynurenine	Dopamine
5-Hydroxytryptamine/Serotonin	Homovanillic acid <sup>a</sup>
5-Hydroxytryptophan	4-Hydroxyphenylacetic acid
Indolelactic acid	4-Hydroxyphenyllactic acid
Indole-3-acetic acid	Metanephrine
3-Indolepropionic acid	3-Methoxy-4-hydroxyphenylglycol
Kynurenine	3-Methoxytyramine <sup>a</sup>
Kynurenic acid <sup>a</sup>	3-O-Methyldopa
Melatonin <sup>a</sup>	Norepinephrine
5-Methoxytryptophol <sup>a</sup>	Tyramine
N-Methylhydroxytryptamine <sup>a</sup>	Tyrosine
Tryptophan	Vanillylmandelic acid
Tryptophol	
Xanthurenic acid	Phenylalanine
Purine	<i>Metabolites</i>
<i>Metabolites</i>	4-Hydroxybenzoic acid
Guanine <sup>a</sup>	2-Hydroxyphenylacetic acid <sup>a</sup>
Guanosine	Cysteine and Methionine
Hypoxanthine	<i>Metabolites</i>
7-Methylxanthine <sup>a</sup>	Cysteine
Paraxanthine	Cystine (sum of reductive and oxidative peaks)
Uric acid	Glutathione (reduced) <sup>a</sup>
Xanthine	Methionine
Xanthosine <sup>a</sup>	Vitamins
	Ascorbic acid <sup>a</sup>
	Ascorbate + hemihydroascorbate
	Alfa-tocopherol
	Gamma-tocopherol

Metabolites from tyrosine, tryptophan, phenylalanine, purine and sulfur amino acid pathways and vitamins analyzed with a liquid chromatography electrochemical array (LCECA) platform.

<sup>a</sup>Non-parametric analyses applied.

( $F = 17.7$ ,  $df = 1$ ,  $p = 3.5 \times 10^{-5}$ , Fig. 2d). For  $p$ -values of metabolite comparisons between all patients and healthy controls not given in the main text, please see online Supplementary Table S1.

### BD v. SCZ

Glutathione (reduced) was lower in BD compared to SCZ ( $p = 0.017$ ), and 5-hydroxytryptophan higher in BD compared to SCZ ( $p = 0.037$ ). Otherwise there were no significant metabolite concentration differences between BD and SCZ.

### BD and SCZ medication-free subsamples v. healthy controls

Of those metabolites with significantly different plasma levels in the total patient sample compared to healthy controls, significantly lower plasma concentration of 3OHKY [SCZ ( $p = 0.021$ ); BD ( $p = 0.013$ ), Fig. 2a], XANU [SZ<sub>diagn</sub> ( $p = 0.007$ ); BD ( $p = 0.0002$ ), Fig. 2b] and VMA [SCZ ( $p = 0.027$ ); BD ( $p = 0.003$ ), Fig. 2c], and significantly higher plasma concentration of XAN [SCZ ( $p = 0.002$ ); BD ( $p = 0.013$ ), Fig. 2d] were found across SCZ and BD medication-free subsamples. MN did not differ significantly from healthy controls in SCZ or BD medication-free subsamples.

Lower plasma concentration of HGA were suggested across SCZ ( $p = 0.011$ ) and BD ( $p = 0.033$ ) medication-free subsamples based on a trend level lower concentration in the total patient

sample ( $p = 0.003$ , online Supplementary Fig. S1). Lower plasma concentrations of dopamine were suggested in all patients (trend level,  $p = 0.00097$ ) compared to healthy controls, but were not replicated across SCZ (ns) and BD ( $p = 0.014$ ) in medication-free subsamples. Otherwise there were no metabolites with significant differences in both the medication-free subsamples v. healthy controls.

### Metabolite concentrations and sample characteristics

Significant associations between metabolite plasma concentrations and sample characteristics not recorded in healthy controls, including affective and psychosis symptoms, are given in Table 3. To control for potential confounding of these variables, metabolite concentrations in subgroups of patients were compared to metabolite concentrations among (all) healthy controls.

### 3OHKY, XANU, VMA, XAN, MN and HGA

**Diet:** Plasma concentration of XANU was significantly lower in patients with healthy ( $p < 0.001$ ) and unhealthy ( $p = 0.002$ ) diet compared to healthy controls.

**Illicit drugs:** Plasma concentrations of 3OHKY were significantly lower in patients with and without the use of illicit drugs compared to healthy controls (both  $p < 0.001$ ).

**Symptoms:** Higher plasma concentrations of MN were associated with less symptoms on several rating scales [GAF-S, SCI-PANSS and CDSS (SCZ)] and higher levels of HGA were associated with lower GAF-S scores; significantly lower concentrations of MN and HGA in patients were shown in the subgroups with symptom scores below (trend level significance for HGA) and above the median symptom scores, compared to healthy controls (Table 3). Plasma concentrations of 3OHKY and XANU were not associated with symptom levels. Sleep pattern measured as early morning awakening was not significantly associated with the metabolite concentrations.

Metabolite concentrations of VMA and XAN were not significantly associated with the demographic or clinical variables. Further details of statistical associations of metabolite concentrations and demographic and clinical variables and subgroup analyses for 3OHKY, XANU, HGA and MN are given in Table 3.

### Discussion

The main findings of the present study are decreased plasma concentration of 3OHKY, XANU and VMA and increased concentration of XAN across diagnostic categories in psychotic disorders. Differences in metabolite concentrations were significant in the overall patient group and confirmed across subsamples of schizophrenia spectrum and bipolar disorders in medication-free individuals. Although not reaching statistical significance after correcting for multiple testing, data were also suggestive of decreases in HGA across SCZ and BD. Decreased concentration was found for MN in the overall patient group; however, without being replicated across the medication-free subsamples.

The present findings in the kynurenine pathway are in line with the pathway being increasingly implicated in the pathogenesis of SCZ and BD in recent years (Erhardt *et al.*, 2017). Kynurenic acid has antagonistic effects on NMDA receptors and seems to be increased at central levels in psychotic disorders (Erhardt *et al.*, 2017; Plitman *et al.*, 2017). In line with the present findings, 3OHKY and its metabolite XANU of the kynurenine pathway were recently reported decreased in serum of patients

**Table 3.** Metabolite plasma concentrations according to demographic and clinical variables in patients

	3OHKY	XANU	HGA	MN
Illicit drugs <sup>a</sup> (Yes/No)	Y < N <sup>††</sup> P < HC <sup>***</sup> / <sup>***</sup>	–	–	–
Alcohol <sup>a</sup> (Yes/No)	–	–	Y < N <sup>†</sup> P < HC <sup>**</sup> / <sup>ns</sup>	–
Diet <sup>b</sup> (Healthy/Unhealthy)	–	H < U <sup>†</sup> P < HC <sup>***</sup> / <sup>**</sup>	–	–
GAF-S (Below/Above median)	–	–	$r = -0.17^{\dagger}$ P < HC <sup>Trend</sup> / <sup>**</sup>	$r = 0.16^{\dagger}$ P < HC <sup>***</sup> / <sup>**</sup>
SCI-PANSS <sup>c</sup> (Below/Above median)	–	–	–	$r = -0.25^{\dagger\dagger}$ P < HC <sup>**</sup> / <sup>***</sup>
CDSS (SCZ) <sup>c</sup> (Below/Above median)	–	–	–	$r = -0.19^{\dagger}$ P < HC <sup>**</sup> / <sup>***</sup>
Affective episodes <sup>d</sup> (Below/Above median)	–	–	$r = -0.15^{\dagger}$ P < HC <sup>Trend</sup> / <sup>**</sup>	–

CDSS, Calgary depression scale for schizophrenia; GAF-S, Global assessment of functioning, symptom scale; HGA, 2,5 dihydroxyphenylacetic acid; ns, not significant; MN, metanephrine;  $r$ , Spearman's rho; SCI-PANSS, Structured clinical interview for the positive and negative syndrome scale; SCZ, Schizophrenia and other psychotic disorders (DSM IV, excluding Psychotic Disorder Due to a General Medical Condition and Substance-Induced Psychotic Disorder); 3OHKY, 3-hydroxykynurenine; XANU, xanthurenic acid

Less-than and greater-than signs ('<', '>') indicate relative level of metabolite concentrations between groups

Underlining explains abbreviations of the categories within each variable.

Analyses of patients (P) v. healthy controls (HC): <sup>Trend</sup> $p < 0.1$ , \* $p < 0.05$ , \*\* $p \leq 0.01$ , \*\*\* $p < 0.001$ .

Analyses within the total patient sample: <sup>†</sup> $p < 0.05$ , <sup>††</sup> $p \leq 0.01$  and <sup>†††</sup> $p < 0.001$ .

<sup>a</sup>Last 2 weeks.

<sup>b</sup>Unhealthy = medium or very unhealthy, patient-rated.

<sup>c</sup>Total score.


<sup>d</sup>Lifetime number.

with SCZ (Fazio *et al.*, 2015). The same study reported decreased XANU in relatives of the patients and suggested XANU as a trait marker and potentially a drug target in SCZ. XANU is reported in neurons in the rodent brain (Gobaille *et al.*, 2008; Roussel *et al.*, 2016), it seem to influence glutamate synaptic transmission (Neale *et al.*, 2013; Fazio *et al.*, 2015) and with a suggested role in cognition (Sathyasaikumar *et al.*, 2017). The present findings replicate deficient levels of 3OHKY and XANU in SCZ, and expand the finding to include BD in line with the psychosis continuum hypothesis (Lichtenstein *et al.*, 2009; Van Snellenberg and de Candia, 2009; Tesli *et al.*, 2014). Although kynurenine pathway dysfunction has previously been linked to BD pathophysiology (Sellgren *et al.*, 2016), this is to the best of our knowledge the first data indicating reduced levels of XANU in BD. Potential mechanisms of kynurenine pathway dysfunction in psychotic disorders include genetic and immune regulatory mechanisms (Wonodi *et al.*, 2011; Kegel *et al.*, 2014; Chaves Filho *et al.*, 2018). Cytokines are regulatory factors in the conversion of tryptophan to N-formylkynurenine, catalyzed by the enzymes indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase (Chaves Filho *et al.*, 2018). In a study of bipolar disorder, Sellgren *et al.* (2016) recently reported an association between the minor allele of a SNP at 1p21.3 and increased kynurenine acid mediated by cytokine activation. Interestingly, immunological pathogenetic mechanisms are amongst the most robust novel findings in psychotic disorders (Dieset *et al.*, 2012; Aberg *et al.*, 2013; Volk *et al.*, 2015; Hartwig *et al.*, 2017). Furthermore, dysregulation of the kynurenine pathway seems to be common to several mental disorders (Aarsland *et al.*, 2015; Lim *et al.*, 2016), indicating shared etiological factors in line with recent evidence of broad genetic correlations across mental disorders (Anttila *et al.*, 2018).

Plasma concentrations of kynurenine and related metabolites other than 3OHKY and XANU, did not differ between patients

and healthy controls in the overall sample or in the medication-free subsamples of SCZ and BD. In line with the present results, a recent systematic review and meta-analysis found no significant difference in peripheral kynurenine acid levels, but increased central levels in SCZ compared to controls (Plitman *et al.*, 2017). In BD, normal blood levels of kynurenine, 3OHKY and anthranilic acid and reduced kynurenine acid relative to healthy controls were recently reported (Birner *et al.*, 2017). In a study using skin fibroblasts, increased production of 3OHK and kynurenine acid was indicated in BD, as well as in SCZ (Johansson *et al.*, 2013). In the present sample, unaltered levels of kynurenine, kynurenine acid and anthranilic acid and decreased levels of 3OHKY were consistent across the overall sample and medication-free subsamples. Further data are needed to determine the characteristics of kynurenine pathway metabolites at peripheral levels (Erhardt *et al.*, 2017); divergent findings between studies could be due to the impact of several factors, including clinical characteristics (Carlborg *et al.*, 2013; Chiappelli *et al.*, 2014) and psychopharmacological agents. Importantly, contrary to the present study, all patients in the samples of Johansson *et al.* (2013) and Birner *et al.* (2017) used psychopharmacological agents, making analyses independent of medication status impossible.

Significantly increased levels of XAN are in line with the established hypothesis of purinergic system dysfunction in psychotic disorders (Michel *et al.*, 2011; Yao *et al.*, 2013; Ortiz *et al.*, 2015; Bartoli *et al.*, 2016). XAN is oxidized to uric acid by the enzyme xanthine oxidase as the last step of purine catabolism (Day *et al.*, 2016). The purinergic system is essential in brain function by various processes including energy metabolism and neurotransmission (Lindberg *et al.*, 2015). Studies of peripheral levels have indicated increased uric acid in BD (Albert *et al.*, 2015; Bartoli *et al.*, 2016, 2017b). Decreased levels have been suggested in SCZ (Reddy *et al.*, 2003; Yao *et al.*, 2010a). Few studies have



**Fig. 2.** Box plots of plasma concentration measured in ng/ml of (a) 3-hydroxykynurenine (3OHKY), (b) xanthurenic acid (XANU), (c) vanillylmandelic acid (VMA) and (d) xanthine (XAN) with significant differences in both Schizophrenia or Schizophrenia spectrum disorders and Bipolar disorder samples relative to healthy controls in medication-free (left side of plots) individuals; the right side of the plots shows the respective blood concentrations of the total sample of patients v. healthy controls independent of medication status. The boxes represent 25<sup>th</sup> and 75<sup>th</sup> percentiles and whiskers represent 1.5 times the interquartile range. Markers for particularly high plasma concentration values (ng/ml) of unmedicated bipolar disorder [(a): 87.0], unmedicated healthy controls [(b): 307.2; (c): 274.3, 348.7, 365.7], all patients [(a): 87.0, 97.6, 149.6, 154.8, 223.4, 236.2; (b): 294.2; (c): 430.7; (d): 359.9] and all healthy controls [(a): 91.2, 112.9; (b): 307.2; (c): 274.3, 348.7, 365.7; (d): 251.3, 378.3] are omitted from the plots to get a suitable scaling of the y-axis.

\* $p < 0.05$ , \*\* $p \leq 0.01$  and \*\*\* $p < 0.001$  v. healthy controls.

reported on XAN in psychotic disorders; however, two studies with mixed samples consisting of about 35% BD, indicated associations between cerebrospinal fluid XAN and hypoxanthine levels and depressive symptomatology and monoamine metabolites (Agren *et al.*, 1983; Niklasson *et al.*, 1983). Furthermore, Yao *et al.* (2010a) reported unaltered XAN, but increased xanthosine plasma levels, a metabolite interconverting to XAN, in neuroleptic-naive first episode psychosis patients. The authors suggest a metabolic shift towards xanthosine. In the present sample, xanthosine levels were similar across patients and healthy controls. Importantly, the current patient sample is larger, and with replicated findings across SCZ and BD in medication-free individuals. Uric acid levels were unaltered in patients compared to healthy controls; however, the finding of increased XAN in both SCZ and BD support purinergic system dysfunction as a trait component in common across psychotic disorders. The underlying mechanism is unclear, but could be linked to alterations in xanthine oxidase activity (Akyol *et al.*, 2002; Brunstein *et al.*, 2005; Michel *et al.*, 2011; Bartoli *et al.*, 2017a).

There were reduced plasma levels of the epinephrine metabolite MN and the in common metabolite VMA of epinephrine and norepinephrine relative to healthy controls in the overall patient sample. However, only VMA was replicated across the diagnostic categories. Norepinephrine has been linked to the pathophysiology of both BD (Manji *et al.*, 2003) and SCZ (Fitzgerald, 2014; Maletic *et al.*, 2017), and the precursor of VMA, 3-Methoxy-4-hydroxyphenylglycol (MHPG) (Goldstein *et al.*, 2003), have been associated with symptom scores of both disorders (Maas *et al.*, 1993; Kurita *et al.*, 2014). Thus, decreased plasma levels of VMA in the present patient sample support the hypothesis of noradrenergic dysfunction in psychosis spectrum disorders. Indicated reductions of HGA in SCZ and BD and of dopamine similarly suggest alterations related to tyrosine metabolism. To the best of our knowledge, the suggested association of HGA with psychotic disorders has not previously been reported.

The current study has noteworthy strengths. Due to the well-characterized sample of related psychotic disorders, we were able to utilize the large size of the overall sample by combining the various diagnostic categories as well as testing associations with an extensive range of potential confounders. Despite phenotypic differences, there are solid evidence of overlapping pathogenetic factors between SCZ and BD (Lichtenstein *et al.*, 2009; Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013), and we were able to confirm findings indicated from the total sample in small well-defined medication-free independent diagnostic subsamples (SZ<sub>diagn</sub> or SCZ and BD). This procedure reduces the possibility of type 1 errors. Importantly, there were only differences between SCZ and BD in two of 52 metabolites (*p*-value levels of 0.02 and 0.04) and no significant differences of 3OHKY, XANU, VMA, MN or XAN.

Conclusions about the direction of effects are tentative due to the cross-sectional design. However, the present significant findings generally involve pathways previously suggested in the pathophysiology of psychotic disorders. Moreover, a broad range of demographic and clinical variables did not seem to explain the main findings. Due to non-normality of some metabolite concentrations and recording of several characteristics only in patients [use of illicit drugs, alcohol and tobacco; diet; level of symptoms (general; affective, including sleep pattern; and psychosis)], we were unable to perform statistical adjustments of these variables in the main analyses. However, separate analyses of associations between demographic and clinical variables and the metabolite

plasma concentrations were performed. Importantly, higher plasma levels of XANU in patients with unhealthy diet and lower levels of 3OHKY in patients using illicit drugs, seem unable to explain lower metabolite levels in patients compared to controls, due to corresponding significant differences in analyses of subgroups of patients (Table 3). Nevertheless, it should be noted that the findings might be prone to residual confounding including stress-related changes (Chiappelli *et al.*, 2014); however, the stress system has been implicated in the pathophysiology of psychotic disorders (van Winkel *et al.*, 2008). The subgroup analyses of medication-free individuals could be susceptible to bias, and the re-identification of significant metabolites in the subsamples could be seen as likely, although the patient subsample were only 25% of the total patient sample. Moreover, the assay variation of the metabolites of the current study was not available; however, the analysis platform has been extensively validated and used in a range of prior studies (see Methods section).

We measured peripheral metabolite levels as compared to central levels. This complicates the interpretation of the results. Metabolites of pathways indicated as dysfunctional in the present analyses, cross the blood-brain barrier (Esler *et al.*, 1995; Gobaille *et al.*, 2008; Bowman *et al.*, 2010), giving grounds for peripheral sampling; however, dynamics are uncertain. Correlations of MN and HGA with symptom measures suggest central communication. In the case of the kynurenine pathway, peripheral kynurenine and probably 3OHKY readily crosses the blood-brain barrier and influence the central kynurenine pathway metabolism (Fukui *et al.*, 1991; Schwarcz *et al.*, 2012; Hestad *et al.*, 2017), indicating the utility of blood sampling, especially as the method enables a large sample without being distressing or conferring risk of serious complications as with lumbar puncture (Wright *et al.*, 2012). Moreover, peripheral measurements is a widely used method in psychiatric research of metabolic processes (Grossman and Potter, 1999; Bicikova *et al.*, 2013; Albert *et al.*, 2015; Fazio *et al.*, 2015; Bartoli *et al.*, 2016; Birner *et al.*, 2017). Also, studies of brain samples have the inherent risk of biases due to the postmortem interval (Lewis, 2002). The selection of metabolites could influence the interpretation of the findings. Several metabolites were not measured, including quinolinic acid and picolinic acid of the kynurenine pathway. Interestingly, a recent study of IgA responses to tryptophan catabolites in deficit and nondeficit schizophrenia reported increased responses to quinolinic acid, picolinic acid, 3OHKY and XANU; however, the relation to serum levels is unclear (Kanchanatawan *et al.*, 2018). The reason for dysregulation of only certain metabolites of the pathways is unclear, but indicate complex regulatory mechanism.

In conclusion, the results indicate dysfunctions of the kynurenine pathway and the noradrenergic and purinergic system in common across SCZ and BD. Of special interest is the association with XANU, a metabolite with recently revealed features relevant for psychotic disorders and previously not focused in BD. The study was able to take advantage of the psychosis continuum model by confirming associations from the total patient sample in medication-free independent subsamples of SCZ and BD, thus strengthening the findings as well as indicating pathophysiological mechanisms in common for the psychosis continuum. The present findings may contribute to the understanding of the pathophysiology of psychotic disorders and the possibility of better pharmacological treatment. Future studies may aim to include large well-characterized samples with targeted metabolomic, immune and genetic data to further disentangle specific gene × environmental mechanisms. Moreover, longitudinal designs



combining peripheral and central assessments would be of major benefit to elucidate the underlying dynamics.

**Supplementary material.** The supplementary material for this article can be found at <https://doi.org/10.1017/S0033291719000400>.

**Author ORCIDs.**  Nils Eiel Steen, 0000-0001-6442-1179

**Acknowledgements.** The authors thank the patients for participating in the study, and the TOP study group members for contributing data collection. The work was supported by the Research Council of Norway, Oslo, Norway (213837, 223273, 217776); the South-East Norway Regional Health Authority, Hamar, Norway (2017-112); and the KG Jebsen Foundation, Bergen, Norway.

**Conflict of interest.** NES, ID, SH, TSJI, OBS, IA, IM, SD, EGJ and MB declare no conflicts of interest. RKD and WM are inventors on patents in the metabolomics field. OAA has received speakers' honorarium from Lundbeck.

## References

- Aarsland TI, Landaas ET, Hegvik TA, Ulvik A, Halmoy A, Ueland PM and Haavik J (2015) Serum concentrations of kynurenines in adult patients with attention-deficit hyperactivity disorder (ADHD): a case-control study. *Behavioral and Brain Functions* 11, 36.
- Aberg KA, Liu Y, Bukszar J, McClay JL, Khachane AN, Andreassen OA, Blackwood D, Corvin A, Djurovic S, Gurling H, Ophoff R, Pato CN, Pato MT, Riley B, Webb T, Kendler K, O'Donovan M, Craddock N, Kirov G, Owen M, Rujescu D, St CD, Werge T, Hultman CM, Delisi LE, Sullivan P and van den Oord EJ (2013) A comprehensive family-based replication study of schizophrenia genes. *JAMA Psychiatry* 70, 573–581.
- Addington D, Addington J and Schissel B (1990) A depression rating scale for schizophrenics. *Schizophrenia Research* 3, 247–251.
- Agren H, Niklasson F and Hallgren R (1983) Brain purinergic activity linked with depressive symptomatology: hypoxanthine and xanthine in CSF of patients with major depressive disorders. *Psychiatry Research* 9, 179–189.
- Akyol O, Herken H, Uz E, Fadillioglu E, Unal S, Sogut S, Ozyurt H and Savas HA (2002) The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 26, 995–1005.
- Albert U, De Cori D, Aguglia A, Barbaro F, Bogetto F and Maina G (2015) Increased uric acid levels in bipolar disorder subjects during different phases of illness. *Journal of Affective Disorders* 173, 170–175.
- Anttila V, Bulik-Sullivan B, Finucane HK, Walters RK, Bras J, Duncan L, Escott-Price V, Falcone GJ, Gormley P, Malik R, Patsopoulos NA, Ripke S, Wei Z, Yu D, Lee PH, Turley P, Grenier-Boley B, Chouraki V, Kamatani Y, Berr C, Letteneur L, Hannequin D, Amouyel P, Boland A, Deleuze JF, Duron E, Vardarajan BN, Reitz C, Goate AM, Huentelman MJ, Kamboh MI, Larson EB, Rogaeva E, St George-Hyslop P, Hakonarson H, Kukull WA, Farrer LA, Barnes LL, Beach TG, Demirci FY, Head E, Hulette CM, Jicha GA, Kauwe JSK, Kaye JA, Leverenz JB, Levey AI, Lieberman AP, Pankratz VS, Poon WW, Quinn JF, Saykin AJ, Schneider LS, Smith AG, Sonnen JA, Stern RA, Van Deerlin VM, Van Eldik LJ, Harold D, Russo G, Rubinsztein DC, Bayer A, Tsolaki M, Proitsi P, Fox NC, Hampel H, Owen MJ, Mead S, Passmore P, Morgan K, Nothen MM, Rossor M, Lupton MK, Hoffmann P, Kornhuber J, Lawlor B, McQuillin A, Al-Chalabi A, Bis JC, Ruiz A, Boada M, Seshadri S, Beiser A, Rice K, van der Lee SJ, De Jager PL, Geschwind DH, Riemenschneider M, Riedel-Heller S, Rotter JI, Ransmayr G, Hyman BT, Cruchaga C, Alegret M, Winsvold B, Palta P, Farh KH, Cuenca-Leon E, Furlotte N, Kurth T, Ligthart L, Terwindt GM, Freilinger T, Ran C, Gordon SD, Borck G, Adams HHH, Lehtimäki T, Wedenoja J, Buring JE, Schurks M, Hrafnsdóttir M, Hottenga JJ, Penninx B, Artto V, Kaunisto M, Vepsäläinen S, Martin NG, Montgomery GW, Kurki MI, Hamalainen E, Huang H, Huang J, Sandor C, Webber C, Muller-Myhsok B, Schreiber S, Salomaa V, Loehrer E, Gobel H, Macaya A, Pozo-Rosich P, Hansen T, Werge T, Kaprio J, Metspalu A, Kubisch C, Ferrari MD, Belin AC, van den Maagdenberg A, Zwart JA, Boomsma D, Eriksson N, Olesen J, Chasman DI, Nyholt DR, Avbersek A, Baum L, Berkovic S, Bradfield J, Buono R, Catarino CB, Cossette P, De Jonghe P, Depondt C, Dlugos D, Ferraro TN, French J, Hjalgrim H, Jamnadas-Khoda J, Kalviainen R, Kunz WS, Lerche H, Leu C, Lindhout D, Lo W, Lowenstein D, McCormack M, Moller RS, Molloy A, Ng PW, Oliver K, Privitera M, Radtke R, Ruppert AK, Sander T, Schachter S, Schankin C, Scheffer J, Schoch S, Sisodiya SM, Smith P, Sperling M, Striano P, Surges R, Thomas GN, Visscher F, Whelan CD, Zara F, Heinzen EL, Marson A, Becker F, Stroink H, Zimprich F, Gasser T, Gibbs R, Heutink P, Martinez M, Morris HR, Sharma M, Ryten M, Mok KY, Pulit S, Bevan S, Holliday E, Attia J, Battey T, Boncoraglio G, Thijs V, Chen WM, Mitchell B, Rothwell P, Sharma P, Sudlow C, Vicente A, Markus H, Kourkoulis C, Pera J, Raffeld M, Silliman S, Boraska Perica V, Thornton LM, Huckins LM, William Rayner N, Lewis CM, Gratacos M, Rybakowski F, Keski-Rahkonen A, Raevuori A, Hudson JI, Reichborn-Kjennerud T, Monteleone P, Karwautz A, Mannik K, Baker JH, O'Toole JK, Trace SE, Davis OSP, Helder SG, Ehrlich S, Herpertz-Dahlmann B, Danner UN, van Elburg AA, Clementi M, Forzan M, Docampo E, Lissowska J, Hauser J, Tortorella A, Maj M, Gonidakis F, Tziouvas K, Papezova H, Yilmaz Z, Wagner G, Cohen-Woods S, Herms S, Julia A, Rabioner R, Dick DM, Ripatti S, Andreassen OA, Espeseth T, Lundervold AJ, Steen VM, Pinto D, Scherer SW, Aschauer H, Schosser A, Alfredsson L, Padyukov L, Halmi KA, Mitchell J, Strober M, Bergen AW, Kaye W, Szatkiewicz JP, Cormand B, Ramos-Quiroga JA, Sanchez-Mora C, Ribases M, Casas M, Hervas A, Arranz MJ, Haavik J, Zayats T, Johansson S, Williams N, Dempfle A, Rothenberger A, Kuntsi J, Oades RD, Banaschewski T, Franke B, Buitelaar JK, Arias Vasquez A, Doyle AE, Reif A, Lesch KP, Freitag C, Rivero O, Palmason H, Romanos M, Langley K, Rietschel M, Witt SH, Dalsgaard S, Borglum AD, Waldman I, Wilmot B, Molly N, Bau CHD, Crosbie J, Schachar R, Loo SK, McGough JJ, Grevet EH, Medland SE, Robinson E, Weiss LA, Bacchelli E, Bailey A, Bal V, Battaglia A, Betancur C, Bolton P, Cantor R, Celestino-Soper P, Dawson G, De Rubeis S, Duque F, Green A, Klauck SM, Leboyer M, Levitt P, Maestrini E, Mane S, De-Luca DM, Parr J, Regan R, Reichenberg A, Sandin S, Vorstman J, Wassink T, Wijsman E, Cook E, Santangelo S, Delorme R, Roge B, Magalhaes T, Arking D, Schulze TG, Thompson RC, Strohmaier J, Matthews K, Melle I, Morris D, Blackwood D, McIntosh A, Bergen SE, Schalling M, Jamain S, Maaser A, Fischer SB, Reinbold CS, Fullerton JM, Guzman-Parra J, Mayoral F, Schofield PR, Cichon S, Muhleisen TW, Degenhardt F, Schumacher J, Bauer M, Mitchell PB, Gershon ES, Rice J, Potash JB, Zandi PP, Craddock N, Ferrier IN, Alda M, Rouleau GA, Turecki G, Ophoff R, Pato C, Anjorin A, Stahl E, Leber M, Czerski PM, Cruceanu C, Jones IR, Posthuma D, Andlauer TFM, Forstner AJ, Streit F, Baune BT, Air T, Sinnamon G, Wray NR, MacIntyre DJ, Porteous D, Homuth G, Rivera M, Grove J, Middeldorp CM, Hickie I, Pergadia M, Mehta D, Smit JH, Jansen R, de Geus E, Dunn E, Li QS, Nauck M, Schoevers RA, Beekman AT, Knowles JA, Viktorin A, Arnold P, Barr CL, Bedoya-Berrio G, Bienvu OJ, Brentani H, Burton C, Camarena B, Cappi C, Cath D, Cavallini M, Cusi D, Darrow S, Denys D, Derks EM, Dietrich A, Fernandez T, Figue M, Freimer N, Gerber G, Grados M, Greenberg E, Hanna GL, Hartmann A, Hirschtritt ME, Hoekstra PJ, Huang A, Huysler C, Illmann C, Jenike M, Kuperman S, Leventhal B, Lochner C, Lyon GJ, Macciardi F, Madruga-Garrido M, Malaty IA, Maras A, McGrath L, Miguel EC, Mir P, Nestadt G, Nicolini H, Okun MS, Pakstis A, Paschou P, Piacentini J, Pittenger C, Plessen K, Ramensky V, Ramos EM, Reus V, Richter MA, Riddle MA, Robertson MM, Roessner V, Rosario F, Samuels JF, Sandor P, Stein DJ, Tsetsos F, Van Nieuwerburgh F, Weatherall S, Wendland JR, Wolanczyk T, Worbe Y, Zai G, Goes FS, McLaughlin N, Nestadt PS, Grabe HJ, Depienne C, Konkashbaev A, Lanzagorta N, Valencia-Duarte A, Bramon E, Buccola N, Cahn W, Cairns M,

- Chong SA, Cohen D, Crespo-Facorro B, Crowley J, Davidson M, DeLisi L, Dinan T, Donohoe G, Drapeau E, Duan J, Haan L, Hougaard D, Karachanak-Yankova S, Khrunin A, Klovins J, Kucinkas V, Lee Chee Keong J, Limborska S, Loughland C, Lonnqvist J, Maher B, Mattheisen M, McDonald C, Murphy KC, Nenadic I, van Os J, Pantelis C, Pato M, Petryshen T, Quedest D, Roussos P, Sanders AR, Schall U, Schwab SG, Sim K, So HC, Stogmann E, Subramaniam M, Toncheva D, Waddington J, Walters J, Weiser M, Cheng W, Cloninger R, Curtis D, Gejman PV, Henskens F, Mattingsdal M, Oh SY, Scott R, Webb B, Breen G, Churchhouse C, Bulik CM, Daly M, Dichgans M, Faraone SV, Guerreiro R, Holmans P, Kendler KS, Koelman B, Mathews CA, Price A, Scharf J, Sklar P, Williams J, Wood NW, Cotsapas C, Palotie A, Smoller JW, Sullivan P, Rosand J, Corvin A, Neale BM, Schott JM, Anney R, Elia J, Grigoriou-Serbanescu M, Edenberg HJ and Murray R (2018) Analysis of shared heritability in common disorders of the brain. *Science* **360**, eaap8757.
- Bartoli F, Crocarno C, Gennaro GM, Castagna G, Trotta G, Clerici M and Carra G (2016) Exploring the association between bipolar disorder and uric acid: a mediation analysis. *Journal of Psychosomatic Research* **84**, 56–59.
- Bartoli F, Crocarno C, Clerici M and Carra G (2017a) Allopurinol as add-on treatment for mania symptoms in bipolar disorder: systematic review and meta-analysis of randomised controlled trials. *British Journal of Psychiatry* **210**, 10–15.
- Bartoli F, Crocarno C, Dakanalis A, Brosio E, Miotto A, Capuzzi E, Clerici M and Carra G (2017b) Purinergic system dysfunctions in subjects with bipolar disorder: a comparative cross-sectional study. *Comprehensive Psychiatry* **73**, 1–6.
- Bicikova M, Hill M, Ripova D, Mohr P and Hampl R (2013) Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. *Journal of Steroid Biochemistry and Molecular Biology* **133**, 77–83.
- Birner A, Platzer M, Bengesser SA, Dalkner N, Fellendorf FT, Queissner R, Pilz R, Rauch P, Maget A, Hamm C, Herzog-Eberhard S, Mangge H, Fuchs D, Moll N, Zelzer S, Schutze G, Schwarz M, Reininghaus B, Kapfhammer HP and Reininghaus EZ (2017) Increased breakdown of kynurenine towards its neurotoxic branch in bipolar disorder. *PLoS One* **12**, e0172699.
- Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullman R, Bressman SS and Flint BM (2008) Metabolomic profiling to develop blood biomarkers for Parkinson's disease. *Brain* **131**, 389–396.
- Bowman GL, Shannon J, Frei B, Kaye JA and Quinn JF (2010) Uric acid as a CNS antioxidant. *Journal of Alzheimer's disease* **19**, 1331–1336.
- Brunstein MG, Ghisolfi ES, Ramos FL and Lara DR (2005) A clinical trial of adjunctive allopurinol therapy for moderately refractory schizophrenia. *Journal of Clinical Psychiatry* **66**, 213–219.
- Cardno AG and Owen MJ (2014) Genetic relationships between schizophrenia, bipolar disorder, and schizoaffective disorder. *Schizophrenia Bulletin* **40**, 504–515.
- Carlborg A, Jokinen J, Jonsson EG, Erhardt S and Nordstrom P (2013) CSF kynurenine acid and suicide risk in schizophrenia spectrum psychosis. *Psychiatry Research* **205**, 165–167.
- Chaves Filho AJM, Lima CNC, Vasconcelos SMM, de Lucena DF, Maes M and Macedo D (2018) IDO chronic immune activation and tryptophan metabolic pathway: a potential pathophysiological link between depression and obesity. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* **80**, 234–249.
- Chiappelli J, Pociavsek A, Nugent KL, Notarangelo FM, Kochunov P, Rowland LM, Schwarcz R and Hong LE (2014) Stress-induced increase in kynurenine acid as a potential biomarker for patients with schizophrenia and distress intolerance. *JAMA Psychiatry* **71**, 761–768.
- Condray R, Dougherty Jr GG, Keshavan MS, Reddy RD, Haas GL, Montrose DM, Matson WR, McEvoy J, Kaddurah-Daouk R and Yao JK (2011) 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naïve patients with schizophrenia. *International Journal of Neuropsychopharmacology* **14**, 756–767.
- Cross-Disorder Group of the Psychiatric Genomics Consortium (2013) Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. *Lancet* **381**, 1371–1379.
- Day RO, Kamel B, Kannagara DR, Williams KM and Graham GG (2016) Xanthine oxidoreductase and its inhibitors: relevance for gout. *Clinical Science (London)* **130**, 2167–2180.
- Dieset I, Djurovic S, Tesli M, Hope S, Mattingsdal M, Michelsen A, Joa I, Larsen TK, Agartz I, Melle I, Rossberg JI, Aukrust P, Andreassen OA and Ueland T (2012) Up-regulation of NOTCH4 gene expression in bipolar disorder. *American Journal of Psychiatry* **169**, 1292–1300.
- Erhardt S, Schwieler L, Imbeault S and Engberg G (2017) The kynurenine pathway in schizophrenia and bipolar disorder. *Neuropharmacology* **112**, 297–306.
- Esler MD, Lambert GW, Ferrier C, Kaye DM, Wallin BG, Kalff V, Kelly MJ and Jennings GL (1995) Central nervous system noradrenergic control of sympathetic outflow in normotensive and hypertensive humans. *Clinical and Experimental Hypertension* **17**, 409–423.
- Fazio F, Lionetto L, Curto M, Iacovelli L, Cavallari M, Zappulla C, Ulivieri M, Napoletano F, Capi M, Corigliano V, Scaccianoce S, Caruso A, Miele J, De Fusco A, Di Menna L, Comparelli A, De Carolis A, Gradini R, Nistico R, De Blasi A, Girardi P, Bruno V, Battaglia G, Nicoletti F and Simmaco M (2015) Xanthurenic acid activates mGlu2/3 metabotropic glutamate receptors and is a potential trait marker for schizophrenia. *Scientific Reports* **5**, 17799.
- First MB, Spitzer RL, Gibbon M and Williams JBW (1995) Structured Clinical Interview for DSM-IV Axis I Disorders: Patient Edition (SCID-P), Version 2.0. *New York: Biometrics Research, New York State Psychiatric Institute*.
- Fitzgerald PJ (2014) Is elevated norepinephrine an etiological factor in some cases of schizophrenia? *Psychiatry Research* **215**, 497–504.
- Fukui S, Schwarcz R, Rapoport SI, Takada Y and Smith QR (1991) Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. *Journal of Neurochemistry* **56**, 2007–2017.
- Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K and Yoshio T (2014) Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. *PLoS One* **9**, e101652.
- Gobaille S, Kemmel V, Brumar D, Dugave C, Aunis D and Maitre M (2008) Xanthurenic acid distribution, transport, accumulation and release in the rat brain. *Journal of Neurochemistry* **105**, 982–993.
- Goldstein DS, Eisenhofer G and Kopin IJ (2003) Sources and significance of plasma levels of catechols and their metabolites in humans. *Journal of Pharmacology and Experimental Therapeutics* **305**, 800–811.
- Grande I, Berk M, Birmaher B and Vieta E (2016) Bipolar disorder. *Lancet* **387**, 1561–1572.
- Grossman F and Potter WZ (1999) Catecholamines in depression: a cumulative study of urinary norepinephrine and its major metabolites in unipolar and bipolar depressed patients versus healthy volunteers at the NIMH. *Psychiatry Research* **87**, 21–27.
- Guest PC, Guest FL and Martins-de SD (2015) Making sense of blood-based proteomics and metabolomics in psychiatric research. *International Journal of Neuropsychopharmacology* **19**, 1–10.
- Gupta M, Neavin D, Liu D, Biernacka J, Hall-Flavin D, Bobo WV, Frye MA, Skime M, Jenkins GD, Batzler A, Kalari K, Matson W, Bhasin SS, Zhu H, Mushiroda T, Nakamura Y, Kubo M, Wang L, Kaddurah-Daouk R and Weinsilboum RM (2016) TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics. *Molecular Psychiatry* **21**, 1717–1725.
- Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P, Deppen P, Preisig M, Ruiz V, Steullet P, Tosic M, Werge T, Cuenod M and Do KQ (2007) Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. *Proceedings of the National Academy of Sciences of the United States of America* **104**, 16621–16626.
- Hartwig FP, Borges MC, Horta BL, Bowden J and Davey SG (2017) Inflammatory biomarkers and risk of schizophrenia: a 2-sample mendelian randomization study. *JAMA Psychiatry* **74**, 1226–1233.
- Hestad KA, Engedal K, Whist JE and Farup PG (2017) The relationships among tryptophan, kynurenine, indoleamine 2,3-dioxygenase, depression, and neuropsychological performance. *Frontiers in Psychology* **8**, 1561.

- Johansen KK, Wang L, Aasly JO, White LR, Matson WR, Henchcliffe C, Beal MF and Bogdanov M (2009) Metabolomic profiling in LRRK2-related Parkinson's disease. *PLoS One* 4, e7551.
- Johansson AS, Owe-Larsson B, Asp L, Kocki T, Adler M, Hetta J, Gardner R, Lundkvist GB, Urbanska EM and Karlsson H (2013) Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: cytokine challenge increases production of 3-hydroxykynurenine. *Journal of Psychiatric Research* 47, 1815–1823.
- Kaddurah-Daouk R and Krishnan KR (2009) Metabolomics: a global biochemical approach to the study of central nervous system diseases. *Neuropsychopharmacology* 34, 173–186.
- Kaddurah-Daouk R, Yuan P, Boyle SH, Matson W, Wang Z, Zeng ZB, Zhu H, Dougherty GG, Yao JK, Chen G, Guitart X, Carlson PJ, Neumeister A, Zarate C, Krishnan RR, Manji HK and Drevets W (2012) Cerebrospinal fluid metabolome in mood disorders-remission state has a unique metabolic profile. *Scientific Reports* 2, 667.
- Kaddurah-Daouk R, Zhu H, Sharma S, Bogdanov M, Rozen SG, Matson W, Oki NO, Motsinger-Reif AA, Churchill E, Lei Z, Appleby D, Kling MA, Trojanowski JQ, Doraiswamy PM and Arnold SE (2013) Alterations in metabolic pathways and networks in Alzheimer's disease. *Translational Psychiatry* 3, e244.
- Kanchanatawan B, Sirivichayakul S, Ruxrungtham K, Carvalho AF, Geffard M, Ormstad H, Anderson G and Maes M (2018) Deficit, but not nondeficit, schizophrenia is characterized by mucosa-associated activation of the tryptophan catabolite (TRYCAT) pathway with highly specific increases in IgA responses directed to picolinic, xanthurenic, and quinolinic acid. *Molecular Neurobiology* 55, 1524–1536.
- Kay SR, Fiszbein A and Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophrenia Bulletin* 13, 261–276.
- Kegel ME, Bhat M, Skogh E, Samuelsson M, Lundberg K, Dahl ML, Sellgren C, Schwieler L, Engberg G, Schuppe-Koistinen I and Erhardt S (2014) Imbalanced kynurenine pathway in schizophrenia. *International Journal of Tryptophan Research* 7, 15–22.
- Kurita M, Nishino S, Numata Y, Okubo Y and Sato T (2014) The noradrenaline metabolite MHPG is a candidate biomarker from the manic to the remission state in bipolar disorder I: a clinical naturalistic study. *PLoS One* 9, e100634.
- Lewis DA (2002) The human brain revisited: opportunities and challenges in postmortem studies of psychiatric disorders. *Neuropsychopharmacology* 26, 143–154.
- Lichtenstein P, Yip BH, Bjork C, Pawitan Y, Cannon TD, Sullivan PF and Hultman CM (2009) Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. *Lancet* 373, 234–239.
- Lieberman JA and First MB (2018) Psychotic disorders. *New England Journal of Medicine* 379, 270–280.
- Lindberg D, Shan D, Ayers-Ringler J, Oliveros A, Benitez J, Prieto M, McCullumsmith R and Choi DS (2015) Purinergic signaling and energy homeostasis in psychiatric disorders. *Current Molecular Medicine* 15, 275–295.
- Liu ML, Zheng P, Liu Z, Xu Y, Mu J, Guo J, Huang T, Meng HQ and Xie P (2014) GC-MS based metabolomics identification of possible novel biomarkers for schizophrenia in peripheral blood mononuclear cells. *Molecular Biosystems* 10, 2398–2406.
- Lim CK, Essa MM, de Paula Martins R, Lovejoy DB, Bilgin AA, Waly MI, Al-Farsi YM, Al-Sharbaty M, Al-Shaffae MA and Guillemin GJ (2016) Altered kynurenine pathway metabolism in autism: implication for immune-induced glutamatergic activity. *Autism Research* 9, 621–631.
- Maas JW, Contreras SA, Miller AL, Berman N, Bowden CL, Javors MA, Seleshi E and Weintraub S (1993) Studies of catecholamine metabolism in schizophrenia/psychosis-I. *Neuropsychopharmacology* 8, 97–109.
- Maletic V, Eramo A, Gwin K, Offord SJ and Duffy RA (2017) The role of norepinephrine and its alpha-adrenergic receptors in the pathophysiology and treatment of major depressive disorder and schizophrenia: a systematic review. *Frontiers in Psychiatry* 8, 42.
- Manji HK, Quiroz JA, Payne JL, Singh J, Lopes BP, Viegas JS and Zarate CA (2003) The underlying neurobiology of bipolar disorder. *World Psychiatry* 2, 136–146.
- Michel TM, Sheldrick AJ, Camara S, Grunblatt E, Schneider F and Riederer P (2011) Alteration of the pro-oxidant xanthine oxidase (XO) in the thalamus and occipital cortex of patients with schizophrenia. *World Journal of Biological Psychiatry* 12, 588–597.
- Motsinger-Reif AA, Zhu H, Kling MA, Matson W, Sharma S, Fiehn O, Reif DM, Appleby DH, Doraiswamy PM, Trojanowski JQ, Kaddurah-Daouk R and Arnold SE (2013) Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer's disease from normal cognitive aging. *Acta Neuropathologica Communications* 1, 28.
- Mukherjee D, Krishnamurthy VB, Millett CE, Reider A, Can A, Groer M, Fuchs D, Postolache TT and Saunders EFH (2018) Total sleep time and kynurenine metabolism associated with mood symptom severity in bipolar disorder. *Bipolar Disorder* 20, 27–34.
- Neale SA, Copeland CS, Uebele VN, Thomson FJ and Salt TE (2013) Modulation of hippocampal synaptic transmission by the kynurenine pathway member xanthurenic acid and other VGLUT inhibitors. *Neuropsychopharmacology* 38, 1060–1067.
- Niklasson F, Agren H and Hallgren R (1983) Purine and monoamine metabolites in cerebrospinal fluid: parallel purinergic and monoaminergic activation in depressive illness? *Journal of Neurology, Neurosurgery and Psychiatry* 46, 255–260.
- Oresic M, Tang J, Seppanen-Laakso T, Mattila I, Saarni SE, Saarni SI, Lonnqvist J, Sysi-Aho M, Hyotylainen T, Perala J and Suvisaari J (2011) Metabolome in schizophrenia and other psychotic disorders: a general population-based study. *Genome Medicine* 3, 19.
- Ortiz R, Ulrich H, Zarate Jr CA and Machado-Vieira R (2015) Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 57, 117–131.
- Owen MJ, Sawa A and Mortensen PB (2016) Schizophrenia. *Lancet* 388, 86–97.
- Pedersen G, Hagtvet KA and Karterud S (2007) Generalizability studies of the global assessment of functioning-split version. *Comprehensive Psychiatry* 48, 88–94.
- Plitman E, Iwata Y, Caravaggio F, Nakajima S, Chung JK, Gerretsen P, Kim J, Takeuchi H, Chakravarty MM, Remington G and Graff-Guerrero A (2017) Kynurenic acid in schizophrenia: a systematic review and meta-analysis. *Schizophrenia Bulletin* 43, 764–777.
- Reddy R, Keshavan M and Yao JK (2003) Reduced plasma antioxidants in first-episode patients with schizophrenia. *Schizophrenia Research* 62, 205–212.
- Rotroff DM, Corum DG, Motsinger-Reif A, Fiehn O, Bottrel N, Drevets WC, Singh J, Salvatore G and Kaddurah-Daouk R (2016) Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants. *Translational Psychiatry* 6, e894.
- Roussel G, Bessede A, Klein C, Maitre M and Mensah-Nyagan AG (2016) Xanthurenic acid is localized in neurons in the central nervous system. *Neuroscience* 329, 226–238.
- Rozen S, Cudkovic ME, Bogdanov M, Matson WR, Kristal BS, Beecher C, Harrison S, Vouros P, Flarakos J, Vigneau-Callahan K, Matson TD, Newhall KM, Beal MF, Brown Jr RH and Kaddurah-Daouk R (2005) Metabolomic analysis and signatures in motor neuron disease. *Metabolomics* 1, 101–108.
- Rush AJ, Gullion CM, Basco MR, Jarrett RB and Trivedi MH (1996) The inventory of depressive symptomatology (IDS): psychometric properties. *Psychological Medicine* 26, 477–486.
- Sathyasaikumar KV, Tararina M, Wu HQ, Neale SA, Weisz F, Salt TE and Schwarcz R (2017) Xanthurenic acid formation from 3-hydroxykynurenine in the mammalian brain: neurochemical characterization and physiological effects. *Neuroscience* 367, 85–97.
- Schwarcz R, Bruno JP, Muchowski PJ and Wu HQ (2012) Kynurenines in the mammalian brain: when physiology meets pathology. *Nature Reviews. Neuroscience* 13, 465–477.
- Sellgren CM, Kegel ME, Bergen SE, Ekman CJ, Olsson S, Larsson M, Vawter MP, Backlund L, Sullivan PF, Sklar P, Smoller JW, Magnusson PK, Hultman CM, Walther-Jallow L, Svensson CI, Lichtenstein P, Schalling M, Engberg G, Erhardt S and Landen M (2016) A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder. *Molecular Psychiatry* 21, 1342–1350.



- Sethi S and Brietzke E (2015) Omics-Based biomarkers: application of metabolomics in neuropsychiatric disorders. *International Journal of Neuropsychopharmacology* **19**, 1–13.
- Tasic L, Pontes JGM, Carvalho MS, Cruz G, Dal MC, Sethi S, Pedrini M, Rizzo LB, Zeni-Graiff M, Asevedo E, Lacerda ALT, Bressan RA, Poppi RJ, Brietzke E and Hayashi MAF (2017) Metabolomics and lipidomics analyses by 1H nuclear magnetic resonance of schizophrenia patient serum reveal potential peripheral biomarkers for diagnosis. *Schizophrenia Research* **185**, 182–189.
- Tesli M, Espeseth T, Bettella F, Mattingsdal M, Aas M, Melle I, Djurovic S and Andreassen OA (2014) Polygenic risk score and the psychosis continuum model. *Acta Psychiatrica Scandinavica* **130**, 311–317.
- Turck CW and Filiou MD (2015) What have mass spectrometry-based proteomics and metabolomics (Not) taught us about psychiatric disorders? *Molecular Neuropsychiatry* **1**, 69–75.
- Van Snellenberg JX and de Candia T (2009) Meta-analytic evidence for familial coaggregation of schizophrenia and bipolar disorder. *Archives of General Psychiatry* **66**, 748–755.
- van Winkel R, Stefanis NC and Myin-Germeys I (2008) Psychosocial stress and psychosis. A review of the neurobiological mechanisms and the evidence for gene-stress interaction. *Schizophrenia Bulletin* **34**, 1095–1105.
- Volk DW, Chitrapu A, Edelson JR, Roman KM, Moroco AE and Lewis DA (2015) Molecular mechanisms and timing of cortical immune activation in schizophrenia. *American Journal of Psychiatry* **172**, 1112–1121.
- Volk DW, Sampson AR, Zhang Y, Edelson JR and Lewis DA (2016) Cortical GABA markers identify a molecular subtype of psychotic and bipolar disorders. *Psychological Medicine* **46**, 2501–2512.
- Wonodi I, Stine OC, Sathyasaikumar KV, Roberts RC, Mitchell BD, Hong LE, Kajii Y, Thaker GK and Schwarcz R (2011) Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. *Archives of General Psychiatry* **68**, 665–674.
- Wright BL, Lai JT and Sinclair AJ (2012) Cerebrospinal fluid and lumbar puncture: a practical review. *Journal of Neurology* **259**, 1530–1545.
- Xu XJ, Zheng P, Ren GP, Liu ML, Mu J, Guo J, Cao D, Liu Z, Meng HQ and Xie P (2014) 2,4-Dihydropyrimidine is a potential urinary metabolite biomarker for diagnosing bipolar disorder. *Molecular Biosystems* **10**, 813–819.
- Yao JK, Dougherty Jr GG, Reddy RD, Keshavan MS, Montrose DM, Matson WR, McEvoy J and Kaddurah-Daouk R (2010a) Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naive patients with schizophrenia. *PLoS One* **5**, e9508.
- Yao JK, Dougherty Jr GG, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J and Kaddurah-Daouk R (2010b) Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. *Molecular Psychiatry* **15**, 938–953.
- Yao JK, Condray R, Dougherty Jr GG, Keshavan MS, Montrose DM, Matson WR, McEvoy J, Kaddurah-Daouk R and Reddy RD (2012) Associations between purine metabolites and clinical symptoms in schizophrenia. *PLoS One* **7**, e42165.
- Yao JK, Dougherty GG, Reddy RD, Matson WR, Kaddurah-Daouk R and Keshavan MS (2013) Associations between purine metabolites and monoamine neurotransmitters in first-episode psychosis. *Frontiers in Cellular Neuroscience* **7**, 90.
- Yoshimi N, Futamura T, Kakumoto K, Salehi AM, Sellgren CM, Holmen-Larsson J, Jakobsson J, Palsson E, Landen M and Hashimoto K (2016) Blood metabolomics analysis identifies abnormalities in the citric acid cycle, urea cycle, and amino acid metabolism in bipolar disorder. *BBA Clinical* **5**, 151–158.
- Young RC, Biggs JT, Ziegler VE and Meyer DA (1978) A rating scale for mania: reliability, validity and sensitivity. *British Journal of Psychiatry* **133**, 429–435.
- Zhang R, Zhang T, Ali AM, Al WM, Pickard B and Watson DG (2016) Metabolomic profiling of post-mortem brain reveals changes in amino acid and glucose metabolism in mental illness compared with controls. *Computational and Structural Biotechnology Journal* **14**, 106–116.
- Zhu H, Bogdanov MB, Boyle SH, Matson W, Sharma S, Matson S, Churchill E, Fiehn O, Rush JA, Krishnan RR, Pickering E, Delnomdedieu M and Kaddurah-Daouk R (2013) Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway. *PLoS One* **8**, e68283.